Merck & Co. will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine. Merck will have the right to research, develop, manufacture and distribute the vaccine, rVSV-EBOV, as well as any follow-on products, the companies said in a joint statement.
Merck buys rights to NewLink's experimental Ebola vaccine
Letter
to the
Editor
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.
Recommended for You
Sponsored Content